Last updated: August 17, 2026 Capricor Therapeutics says the FDA is willing to review an amended deramiocel BLA and extend the August 22, 2026 action
Last updated: August 14, 2026 In an August 13 bankruptcy auction, PTC Therapeutics agreed to pay up to $211 million for Sangamo’s Fabry disease gene
Last updated: August 13, 2026 Definium Therapeutics’ DT120, an orally disintegrating tablet of lysergide, reduced Hamilton Anxiety Rating Scale scores by 11.6 points versus 6.2
Last updated: August 12, 2026 The FDA rejected ITM’s radioligand therapy ITM-11 and forced Scholar Rock to drop a fill finish site from its apitegromab
Sionna’s SION-719 missed on sweat chloride as a Trikafta add on. Full data on the miss, Tenax’s Phase 3, Silence’s PV win, and Grail’s FDA panel date.
Last updated: August 10, 2026 Quick answer: The FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) on August 6, 2026, in combination with nivolumab
Last updated: August 7, 2026 Quick answer: Eli Lilly reported $23 billion in second quarter 2026 revenue, with shares rising nearly 5% to $1,170 and
The FDA’s advisory committee process just produced the most contradictory week of the year, and it landed exactly where we said the uneven reset would
The dealmaking story keeps widening, and today it moved down market. Supernus and Indivior agreed to an all stock merger of equals that creates a
The Financial Times reported that AstraZeneca and Bristol Myers Squibb have been in talks to combine, a deal that would create a pharmaceutical group valued
